SHR-4394

· Jiangsu HengRui Medicine Co., Ltd.

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for SHR-4394, covering 2025-02-27 to 2026-04-21. Get the full timeline:

Most recent: Clinical Trial Update: A Clinical Study of SHR-4394 in Combination With Anti-tumor Therapy in Prostate Cancer [Phase 1, Phase 2]